AstraZeneca (NASDAQ: AZN) reported Q1 EPS of $2.49, $1.39 better than the analyst estimate of $1.10. Revenue for the quarter came in at $13.59 billion versus the consensus estimate of $13.77 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.